

Group I: Claims 26-55, drawn to a method for identifying organic non-peptide compounds useful in the treatment of cancer.

Group II: Claim 56, drawn to a method of evaluating whether an organic compound can promote a wild-type activity in a mutant form of a mammalian protein of the p53 family.

Applicants hereby elect without traverse to prosecute the claims of Group I in this application. Applicants election of Group I subject matter at present, however, does not prejudice applicants' ability to file divisional or continuation applications to unelected subject matter.

Applicants do not believe any additional fees are due in connection with the filing of this response to the April 11, 2003 Restriction Requirement. However, if any fee is due, the Examiner is authorized to charge the fee to applicants' Deposit Account No. 16-1445.

CONCLUSION

Applicants respectfully request prompt consideration of the pending claims and early allowance of the application.

If the Examiner wishes to comment or discuss any aspect of this application or response, applicants' undersigned attorney invites the Examiner to call him at the telephone number provided below.

Respectfully submitted,

Date: May 8, 2003



E. Victor Donahue
Attorney for Applicants
Reg. No. 35,492

Pfizer Inc
Patent Dept., 5th Floor
150 East 42nd Street
New York, NY 10017
(212) 733-2739